Enzolytics Inc (ENZC)

[falon]

Priceless

Charles is a visionary and Lonza sees the light and maybe setting itself up to be part of ENZC processes for years to come.

It will take many companies to work on the products ENZC will be producing.

Just think about what Charles said about the licensees already lining up to get a piece of the ever growing pie.

Every time ENZC reaches a significant milestone they become more and more valuble.

The PICTURE of ENZC was BLURRY when they gave us Milestones timelines on 4/19/2021:


We are encouraged by the positive feedback received from pharmaceutical companies who have acknowledged an interest in partnering upon achievement of defined milestones. The milestones we have set include the following:

Monoclonal Antibodies for Treatment of HIV Milestones

1st Milestone: Testing of anti-HIV Monoclonal Antibodies at University of Montana

Status: in process. Time to completion: 1 month

2nd Milestone: Broad-based neutralization testing of existing anti-HIV Monoclonal Antibodies at University of Strasbourg, France

Status; in process. Time to completion: 2 months

3rd Milestone: Animal Studies of anti-HIV Monoclonal Antibodies at California National Primate Research Center, University of Southern California

Time to completion: 6 months following in vitro testing in process.

4th Milestone: Using Artificial Intelligence, identification of additional conserved immutable target sites (epitopes) on the HIV-1 virus

Status: Completed

5th Milestone: Production of additional Monoclonal Antibodies targeting identified sites (epitopes) on the HIV virus

Status: in process. Time to completion: 5-6 months

COVID-19

We are proud of the significant advances we have made in the development of Monoclonal Antibodies for treating Covid-19. We have reported that the Monoclonal Antibodies being produced by the Company will target immutable, conserved sites on SARS-CoV-2 (Coronavirus) that exist on the variant strains of the virus from the UK, Brazil, and South African.

These findings are considered highly significant in that the Center for Disease Control ("CDC") has reported these "variants of concern" are ones "for which there is evidence of an increase in transmissibility, more severe disease (meaning increased hospitalizations or deaths), a significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures."

Our AI platform developed in collaboration with Denver Scientific has been one of our many successes. The patentable discoveries will be significant in our ongoing partnering dialogue with pharmaceutical companies interested in treatments for the Coronavirus and numerous other infectious diseases.

We intent to expedite our development of anti-Coronavirus Monoclonal Antibodies including an eventual fast-track clinical trial to progress to market.

SARS-CoV-2 (Coronavirus) Monoclonal Antibodies Milestones

1st Milestone: Using Artificial Intelligence, identification of conserved immutable target sites (epitopes) on the Coronavirus

Status: Completed

2nd Milestone: Production of Monoclonal Antibodies targeting identified sites (epitopes) on the SARS-CoV-2 virus

Status: In process. Time to completion: 3-4 months

3rd Milestone: Fast-Track Clinical Studies

Time to Completion: 6 months following production of Monoclonal Antibodies

ITV-1 anti-HIV Therapeutics

Clinical trials are planned for the Company's patented anti-HIV therapeutics ITV-1. Earlier this year, we announced the execution of Articles of Association to form International Medical Partners ("IMPL"), a Bulgarian Limited Liability Company of which the Company is 50% owner. The Company's partners in IMBL will fund the total cost of the Clinical trials under the European Medicine Agency (the "EMA") standards and the application cost for the EMA permit for the Company's ITV-1 patented therapeutics for treating HIV. Under the Mutual Recognition Agreement (the "MRA") between the EMA and the United States Federal Drug Administration (the "FDA"), the Company believes that issuance of the EMA permit for the ITV-1 compound could qualify ENZC's treatment for recognition by the FDA. IMBL has entered negotiations to engage a CRO to begin the clinical trials required under EMA standards.

We will have a definitive timeline for the expected date of initiation and completion of clinical trials in the coming weeks.

Production of Monoclonal Antibodies for HTLV-1/2

We are committed to developing "universal, durable and broadly neutralizing" Monoclonal Antibodies for many infectious diseases. We have an "intent to partner" agreement with a pharmaceutical company to create Monoclonal Antibodies against HTLV-1/2. We expect to complete the production by the end of 2021.

Monoclonal Antibodies for HTLV-1/2

1st Milestone: Using Artificial Intelligence, identification of conserved immutable target sites (epitopes) on the HTLV1/2 virus

Time to Completion: 2-3 months

2nd Milestone: Creation of anti-HTLV1/2 Monoclonal Antibodies

Time to completion: 6-8 months following identification of target epitopes

CEO Charles Cotropia said, "The strength of our company lies in our multiple technology platforms and the ability to produce fully human Monoclonal Antibodies against conserved and immutable targets on identified viruses. The viruses that may be addressed using our technology range from HIV to the Coronavirus to HTLV-1/2 to Ebola and many more. These numerous targeted viruses and bacteria are listed on our website [http://enzolytics.com/proprietary-therapeutics/]. We will continue to provide updates on our developments and progress toward completing the milestones we have set. We thank all our shareholders for their ongoing support of our Company and its technologies."

The PICTURE of ENZC was very, very CLEAR when they gave us an update timelines on 7/22/2021:



It is All about the MILESTONES!!!